These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The value of electrochemical skin conductance measurement using Sudoscan® in the assessment of patients with familial amyloid polyneuropathy. Lefaucheur JP; Zouari HG; Gorram F; Nordine T; Damy T; Planté-Bordeneuve V Clin Neurophysiol; 2018 Aug; 129(8):1565-1569. PubMed ID: 29883834 [TBL] [Abstract][Full Text] [Related]
25. Extremely Early Onset Transthyretin Familial Amyloid Polyneuropathy with a Leu55Pro Mutation: A Pediatric Case Report and Literature Review. Lee YJ; Oh J; Hwang SK; Lee EJ; Yang DH; Kim YJ; Kwon S; Hyun MC Neuropediatrics; 2019 Oct; 50(5):322-326. PubMed ID: 31319424 [TBL] [Abstract][Full Text] [Related]
26. [Transthyretin familial amyloid polyneuropathy]. Kopishinskaya SV Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(10):82-89. PubMed ID: 30499502 [TBL] [Abstract][Full Text] [Related]
27. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study. Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161 [TBL] [Abstract][Full Text] [Related]
34. Secondary glaucoma in patients with familial amyloidotic polyneuropathy. Kimura A; Ando E; Fukushima M; Koga T; Hirata A; Arimura K; Ando Y; Negi A; Tanihara H Arch Ophthalmol; 2003 Mar; 121(3):351-6. PubMed ID: 12617705 [TBL] [Abstract][Full Text] [Related]
35. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. Dohrn MF; Röcken C; De Bleecker JL; Martin JJ; Vorgerd M; Van den Bergh PY; Ferbert A; Hinderhofer K; Schröder JM; Weis J; Schulz JB; Claeys KG J Neurol; 2013 Dec; 260(12):3093-108. PubMed ID: 24101130 [TBL] [Abstract][Full Text] [Related]
36. Familial amyloidosis with polyneuropathy type 1 caused by transthyretin mutation Val50Met (Val30Met): 4 cases in a non-endemic area. Andrés N; Poza JJ; Martí Massó JF Neurologia (Engl Ed); 2018; 33(9):583-589. PubMed ID: 27793437 [TBL] [Abstract][Full Text] [Related]
37. [Two elderly cases of transthyretin amyloid polyneuropathy without a family history]. Nomura T; Oshima Y; Yoshino M; Matsushima M; Yabe I; Sasaki H Rinsho Shinkeigaku; 2020 Oct; 60(10):688-692. PubMed ID: 32893242 [TBL] [Abstract][Full Text] [Related]
38. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy. Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783 [TBL] [Abstract][Full Text] [Related]
39. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser. Yang NC; Lee MJ; Chao CC; Chuang YT; Lin WM; Chang MF; Hsieh PC; Kan HW; Lin YH; Yang CC; Chiu MJ; Liou HH; Hsieh ST Neurology; 2010 Aug; 75(6):532-8. PubMed ID: 20697105 [TBL] [Abstract][Full Text] [Related]
40. [Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina]. Chaves M; Bettini M; Marciano S; Sáez S; Cristiano E; Rugiero M Medicina (B Aires); 2016; 76(2):105-8. PubMed ID: 27135849 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]